公开(公告)号：EP4373524A1

公开(公告)日：2024-05-29

申请号：EP22846562.1

申请日：2022-07-20

Applicant: Pinnacle Biologics, Inc.

Inventor： KUTSCHERA, Glenn, M. ,  MANG, Thomas, S.

IPC: A61K41/00 ,  A61N5/06 ,  A61K8/04

CPC classification number: A61P31/02 ,  A61K41/0071 ,  A61K47/10 ,  A61K47/26 ,  A61K47/24 ,  A61K47/38 ,  A61K47/32 ,  A61K9/0014 ,  A61K9/06 ,  A61K47/20

公开(公告)号：EP4371558A1

公开(公告)日：2024-05-22

申请号：EP22841360.5

申请日：2022-07-12

Applicant: Shanghai Aurora Biotechnology Co., Ltd.

Inventor： GUO, Zhen ,  XIE, Wenfeng ,  XIAO, Xiaoling ,  WANG, Tingting ,  YING, Shuhuan

IPC: A61K9/22 ,  A61K31/41 ,  A61K31/216 ,  A61K9/44 ,  A61K9/36 ,  A61K47/36 ,  A61K47/38 ,  A61P9/04

CPC classification number: A61P9/04 ,  A61K9/209 ,  A61K9/50 ,  A61K31/216 ,  A61K9/20 ,  A61K47/32 ,  A61K47/10 ,  A61K47/02 ,  A61K47/12 ,  A61K9/28 ,  A61K9/2072 ,  A61K31/41 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38

Abstract: A sacubitril valsartan sodium sustained-release composition, and a preparation method therefor and the use thereof. The composition is a 24-hour sustained-release drug. Dissolution of sacubitril and valsartan simultaneously satisfies the following three features: A) dissolving no more than 40% of pharmaceutical active ingredients within 2 hours; B) dissolving 20%-75% of the pharmaceutical active ingredients within 8 hours; and C) dissolving not less than 65% of the pharmaceutical active ingredients within 24 hours. Compared with common gel sustained-release dosage forms, sacubitril and valsartan in the composition can achieve synchronous sustained release; moreover, the drug release behavior is not affected by factors such as the pH of a medium environment, gastrointestinal peristalsis, and foods, the in vivo and in vitro correlation is good, gentle release within 24 hours is achieved, and the therapeutic effect is good. Compared with common immediate-release formulations, the medication frequency is reduced, the patient compliance is improved, the medication compliance is improved for people having difficulty in swallowing such as the elderly and children, it is convenient to medicate, the toxic side effects are small, and the market prospects are good.

公开(公告)号：EP4364738A2

公开(公告)日：2024-05-08

申请号：EP23219522.2

申请日：2021-06-10

Applicant: Auspex Pharmaceuticals, Inc.

Inventor： SHAH, Parag ,  JOSHI, Mayank ,  PATTANAYEK, Soumen ,  PATEL, Divyang ,  PANDITA, Sandeep

IPC: A61K31/4745

CPC classification number: A61K9/0004 ,  A61K9/2086 ,  A61K9/2866 ,  A61K31/4747 ,  A61K47/10 ,  A61K47/38 ,  A61P25/14 ,  A61P25/28 ,  A61K31/4745

Abstract: Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once-daily basis, the dosage forms provide a favorable pharmacokinetic profile for the active agent indicating treatment efficacy over an extended period of time.

公开(公告)号：EP4356908A1

公开(公告)日：2024-04-24

申请号：EP22825019.7

申请日：2022-06-15

Applicant: Toray Industries, Inc.

Inventor： MATSUURA Takumi ,  KURUMATANI Hajimu

IPC: A61K31/343 ,  A61K9/42 ,  A61K47/10 ,  A61K47/12 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38 ,  A61K47/44 ,  A61P13/12 ,  A61P33/00

CPC classification number: A61K31/343 ,  A61P33/00 ,  A61K47/44 ,  A61K47/10 ,  A61K47/12 ,  A61K47/26 ,  A61K47/36 ,  A61P13/12 ,  A61K47/38 ,  A61K9/28

Abstract: The invention provides a therapeutic method for a cat with chronic kidney disease to inhibit progression of chronic kidney disease into IRIS stage 4 or kidney death of a cat or improve the overall survival rate or the observed survival rate. The therapeutic method for a cat with chronic kidney disease inhibits progression of chronic kidney disease into IRIS stage 4 or kidney death of a cat by administering a therapeutic agent comprising, as an active ingredient, a compound represented by the formula (I) to a cat with stage 3 or 4 chronic kidney disease defined by the staging system established by the International Renal Interest Society (the IRIS staging) in an amount of 90 to 130 µg of the compound represented by the formula (I) daily:

wherein R represents hydrogen or a pharmacologically acceptable cation.

公开(公告)号：EP4356907A1

公开(公告)日：2024-04-24

申请号：EP23219005.8

申请日：2015-09-04

Applicant: LobSor Pharmaceuticals Aktiebolag

Inventor： BOLSÖY, Roger

IPC: A61K31/198 ,  A61K31/277 ,  A61K31/165 ,  A61K45/06 ,  A61K9/06 ,  A61K47/38 ,  A61P25/16

CPC classification number: A61K9/06 ,  A61K31/277 ,  A61K9/0019 ,  A61K47/38 ,  A61K9/0024 ,  A61K45/06 ,  A61K31/198 ,  A61P25/16 ,  A61P25/28 ,  A61K31/165

Abstract: A pharmaceutical gel composition for intra-intestinal administration comprises (i) a dopamine replacement agents, (ii) a dopamine decarboxylase inhibitor (DDI), and (iii) a COMT inhibitor.

公开(公告)号：EP4353233A1

公开(公告)日：2024-04-17

申请号：EP22820243.8

申请日：2022-06-08

Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA

Inventor： SAKAI, Kenichi ,  UCHIYAMA, Hiromasa ,  MINODA, Tomoyuki ,  YOSHIKAWA, Mayumi ,  NATSUMOTO, Shigemori ,  TAKANO, Ryusuke

IPC: A61K31/506 ,  A61K9/14 ,  A61K9/16 ,  A61K9/20 ,  A61K9/48 ,  A61K47/04 ,  A61K47/12 ,  A61K47/14 ,  A61K47/20 ,  A61K47/26 ,  A61K47/32 ,  A61K47/34 ,  A61K47/36 ,  A61K47/38 ,  A61P3/00 ,  A61P43/00

CPC classification number: A61P43/00 ,  A61K47/20 ,  A61K9/20 ,  A61K47/32 ,  A61K47/02 ,  A61K47/12 ,  A61K47/34 ,  A61K31/506 ,  A61K9/14 ,  A61P3/00 ,  A61K9/48 ,  A61K9/16 ,  A61K47/26 ,  A61K47/36 ,  A61K47/14 ,  A61K47/38

Abstract: The present invention provides a pharmaceutical composition having excellent dissolution property and content uniformity and a production method thereof by mixing a p-toluenesulfonate of 7-[[2,3-difluoro-4-[2-[2-methoxyethyl(methyl)amino]ethoxy]phenyl]methyl] -10-hydroxy-6-methyl-8-oxo-N-[4-(trifluoromethyl)-2-[6-(trifluoromethyl)pyrimidin-4-yl]phenyl]-6,7-diazaspiro[4,5]deca-9-ene-9-carboxamide with specific additives, and formulating the mixture.

公开(公告)号：EP4351585A1

公开(公告)日：2024-04-17

申请号：EP22738175.3

申请日：2022-06-10

Applicant: Orphai Therapeutics Inc.

Inventor： FANDRICK, Keith ,  BECKETT, Paul ,  MELVIN, Lawrence, S., Jr. ,  YOUNG, Peter, Ronald ,  EDWARDS, Joan

IPC: A61K31/5377 ,  A61K9/48 ,  A61K9/20 ,  A61K47/02 ,  A61K47/36 ,  A61K47/38 ,  A61K47/12 ,  A61K47/32 ,  A61P25/28 ,  A61P35/00 ,  A61P31/14 ,  A61K9/19 ,  A61K9/00 ,  A61K47/26 ,  A61K47/42

CPC classification number: A61K9/0056 ,  A61K47/26 ,  A61K47/42 ,  A61K9/19 ,  A61K31/5377 ,  A61K47/02 ,  A61K47/36 ,  A61K47/38 ,  A61K47/12 ,  A61K47/32 ,  A61P25/28 ,  A61P35/00 ,  A61P31/14

公开(公告)号：EP4351532A1

公开(公告)日：2024-04-17

申请号：EP22747740.3

申请日：2022-07-22

Applicant: SiSaf Ltd

Inventor： SAFFIE-SIEBERT, Roghieh Suzanne ,  SUTERA, Flavia

IPC: A61K9/51 ,  A61K31/713 ,  C12N15/11 ,  A61K8/25 ,  A61K9/19 ,  A61K47/32

CPC classification number: A61K31/713 ,  C12N15/111 ,  C12N2310/1420130101 ,  A61K9/19 ,  A61K9/06 ,  A61K47/36 ,  A61K39/00 ,  A61K9/143 ,  A61K9/145 ,  A61K47/38 ,  A61K9/0019

公开(公告)号：EP3409294A1

公开(公告)日：2018-12-05

申请号：EP17461543.5

申请日：2017-06-01

Applicant: PRZEDSIEBIORSTWO FARMACEUTYCZNE LEK-AM SP Z O. O.

Inventor： LECHNIO, Joanna ,  WI NIEWSKA, Anna ,  NICHTHAUSER, Joanna ,  URBA SKA, Agnieszka ,  OSINSKI, Andrzej ,  HEJDUK, Arkadiusz ,  MILANOWSKI, Bart omiej ,  JAKUBOWSKA, Emilia ,  LULEK, Janina

IPC: A61K47/38 ,  A61K9/20 ,  A61K9/28 ,  A61K31/4709 ,  A61K9/14

CPC classification number: A61K9/20 ,  A61K9/146 ,  A61K9/2004 ,  A61K9/2013 ,  A61K9/2022 ,  A61K9/2095 ,  A61K9/2866 ,  A61K31/4709 ,  A61K47/38

Abstract: Pharmaceutical tablet composition comprising a pharmaceutically acceptable ingredient - cilostazol in the form of particles having the following particle size distribution:
D 0.5 10-30 µm
D 0.9 40-70 µm and bioavailability of the commercial product reference drug Pletal

公开(公告)号：EP3409293A1

公开(公告)日：2018-12-05

申请号：EP18174611.6

申请日：2018-05-28

Applicant: UNIVERSITA' DEGLI STUDI DI CAGLIARI

Inventor： MANCONI, Maria ,  Manca, Maria Letizia ,  CADDEO, Carla ,  Fadda, Anna Maria

IPC: A61K47/36 ,  A61K36/9066 ,  A61K9/127 ,  A61K47/22 ,  A61K47/32 ,  A61K47/38

CPC classification number: A61K9/1271 ,  A61K36/87 ,  A61K47/22 ,  A61K47/32 ,  A61K47/36 ,  A61K47/38

Abstract: The present invention relates to the preparation of complexes of phospholipids, water-soluble dextrin fibers and antioxidizing substances of natural origin aggregated in the form of lamellar vesicles, which are intended for the formulation of nutraceutical and/or pharmaceutical products for oral use.
More specifically, the present invention relates to the preparation of dispersions of said vesicular complexes in substantially aqueous solvents; to the lyophilization thereof for obtaining solid and stable complexes formed by phospholipids, dextrin fibers and antioxidizing substances; to the extemporaneous hydration of said lyophilized solid complexes for reconstituting said substantially water-based vesicular dispersion just before use.